Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 259,602 | 250,401 | 241,963 | 205,831 | 231,041 |
| Cost of Goods | 21,803 | 18,857 | 18,230 | 22,951 | 17,890 |
| Gross Profit | 237,799 | 231,544 | 223,733 | 182,880 | 213,151 |
| Operating Expenses | 85,099 | 200,757 | 193,526 | 168,621 | 179,097 |
| Operating Income | 153,503 | 31,644 | 30,437 | 15,210 | 34,944 |
| Other Income | 7,582 | 7,162 | 6,745 | 5,792 | 4,759 |
| Pre-tax Income | 161,085 | 38,806 | 37,182 | 21,002 | 39,703 |
| Income Tax | 17,343 | 6,041 | 3,793 | 4,447 | -6,094 |
| Net Income Continuous | 143,742 | 32,765 | 33,389 | 16,555 | 45,797 |
| Net Income | $143,742 | $32,765 | $33,389 | $16,555 | $45,797 |
| EPS Basic Total Ops | 0.87 | 0.20 | 0.20 | 0.10 | 0.29 |
| EPS Basic Continuous Ops | 0.87 | 0.20 | 0.20 | 0.10 | 0.28 |
| EPS Diluted Total Ops | 0.86 | 0.20 | 0.20 | 0.10 | 0.29 |
| EPS Diluted Continuous Ops | 0.86 | 0.20 | 0.20 | 0.10 | 0.28 |
| EPS Diluted Before Non-Recurring Items | 0.17 | 0.20 | 0.20 | N/A | N/A |
| EBITDA(a) | $155,900 | $31,467 | $31,054 | $18,952 | $34,802 |